Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06678048 | Arsenous Acid for Refractory Triple-Negative Breast Cancer | recruiting | Phase 2 | 12 | Sun Yat-sen UniversityOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06993714 | 3D-printed Biodegradable Breast Implants for Breast Restoration | recruiting | Phase 2 | 120 | Xijing HospitalOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT07005583 |
| not yet recruiting |
| Phase 2 |
| 46 |
| Tianjin Medical University Cancer Institute and HospitalOTHER |
| 1 |
| Jun 5, 2025 |
| clinicaltrials |
| NCT02546232 | Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting | active not recruiting | Phase 2 | 196 | Oslo University HospitalOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06677879 | A Prospective Cohort Study of Proton and Photon Therapy for Left-sided Breast Cancer. | recruiting | Phase 2 | 780 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06049355 | EMBRACE: Exercising Together | recruiting | Phase 2 | 400 | OHSU Knight Cancer InstituteOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06992336 | Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy | recruiting | Phase 2 | 411 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06367088 | Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer | recruiting | Phase 2 | 27 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT05251714 | CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 44 | Treadwell Therapeutics, IncINDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT06977542 | Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer | not yet recruiting | Phase 2 | 53 | Fudan UniversityOTHER | 0 | May 18, 2025 | clinicaltrials |
| NCT06975475 | SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases | not yet recruiting | Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | May 16, 2025 | clinicaltrials |
| NCT06976021 | Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy(INTROSPECTION) | not yet recruiting | Phase 2 | 60 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 0 | May 16, 2025 | clinicaltrials |
| NCT04947189 | Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer(4CAST) | recruiting | Phase 1 / Phase 2 | 65 | St Vincent's Hospital, SydneyOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT05463601 | Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer | active not recruiting | Phase 2 | 132 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06165419 | Definitive Radiation for High-Risk Spine Metastases | recruiting | Phase 2 | 26 | Stony Brook UniversityOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06958445 | Prevention of Oral Mucositis and Improvement of Quality of Life for Patients With Breast Cancer Undergoing Adjuvant Radiotherapy(SAFE) | enrolling by invitation | Phase 2 | 90 | Taipei City HospitalOTHER_GOV | 1 | May 6, 2025 | clinicaltrials |
| NCT06958627 | The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study(any) | recruiting | Phase 2 / Phase 3 | 964 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT04503265 | A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 122 | AtlasMedx, IncorporatedINDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT06207734 | Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer | recruiting | Phase 2 | 120 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT06225284 | Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients(ESCALATE) | recruiting | Phase 2 | 124 | National Taiwan University HospitalOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT05535413 | UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases | recruiting | Phase 1 / Phase 2 | 30 | Hunan Cancer HospitalOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT03161353 | Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.(PHERGain) | active not recruiting | Phase 2 | 377 | MedSIROTHER | 7 | Apr 23, 2025 | clinicaltrials |
| NCT05288777 | Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer(Breast53) | recruiting | Phase 2 / Phase 3 | 45 | University of VirginiaOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT04892693 | Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency | recruiting | Phase 2 | 70 | Seoul National University HospitalOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT05536128 | Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor(Post-CDK) | recruiting | Phase 2 | 64 | Seoul National University HospitalOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT05013255 | Pioglitazone Therapy Targeting Fatigue in Breast Cancer | recruiting | Phase 2 | 30 | West Virginia UniversityOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT04680442 | Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction(SCHOLAR-2) | recruiting | Phase 2 | 130 | Population Health Research InstituteOTHER | 3 | Apr 6, 2025 | clinicaltrials |
| NCT04445844 | INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study | active not recruiting | Phase 2 | 25 | Mridula George, MDOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT05252988 | Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib(DIANER) | active not recruiting | Phase 2 | 177 | Spanish Breast Cancer Research GroupOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06811870 | A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Breast Cancer Patients | recruiting | Phase 1 / Phase 2 | 161 | Guangdong Provincial People's HospitalOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05955170 | Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer(TUC-TOC) | recruiting | Phase 2 | 66 | Institut CurieOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT06632405 | A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC | not yet recruiting | Phase 2 | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Mar 26, 2025 | clinicaltrials |
| NCT06788197 | A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 52 | Henan Cancer HospitalOTHER_GOV | 0 | Mar 26, 2025 | clinicaltrials |
| NCT06890871 | Radiotherapy with Immunotherapy and Anti-Angiogenic Therapy for Advanced HER2-Negative Breast Cancer: a Single-Arm Study | enrolling by invitation | Phase 1 / Phase 2 | 25 | Zhongnan HospitalOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05332561 | Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) | recruiting | Phase 2 | 240 | German Cancer Research CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT05485766 | Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer | recruiting | Phase 2 | 23 | Okayama UniversityOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06775236 | Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 410 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Mar 19, 2025 | clinicaltrials |
| NCT06880029 | Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy(CIRCADIAN) | recruiting | Phase 1 / Phase 2 | 20 | Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.OTHER_GOV | 1 | Mar 19, 2025 | clinicaltrials |
| NCT05816655 | Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer | recruiting | Phase 2 | 202 | Korea University Guro HospitalOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT00999804 | Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy(HELEX) | active not recruiting | Phase 2 | 128 | Baylor Breast Care CenterOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT02547987 | Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer(CADENCE) | active not recruiting | Phase 2 | 25 | Mothaffar RimawiOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05918133 | A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC | active not recruiting | Phase 1 / Phase 2 | 42 | Biotheus Inc.INDUSTRY | 1 | Mar 11, 2025 | clinicaltrials |
| NCT05918328 | Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC | recruiting | Phase 2 | 610 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06193525 | FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test(FUTURE) | recruiting | Phase 2 | 66 | Erasmus Medical CenterOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06851299 | The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer. | recruiting | Phase 2 | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT03324425 | Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer(SIMPHONY) | active not recruiting | Phase 2 | 5 | Baylor Breast Care CenterOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04807192 | CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC) | active not recruiting | Phase 2 | 40 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT05020860 | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer(RESPONSE) | recruiting | Phase 2 | 185 | Baylor Breast Care CenterOTHER | 1 | Feb 27, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jun 6, 2025source: clinicaltrials